Conmed Corp CNMD
We take great care to ensure that the data presented and summarized in this overview for CONMED Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CNMD
View all-
Black Rock Inc. New York, NY4.99MShares$270 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.55MShares$192 Million0.0% of portfolio
-
Earnest Partners LLC Atlanta, GA2.83MShares$153 Million0.7% of portfolio
-
Fuller & Thaler Asset Management, Inc. San Mateo, CA1.74MShares$94 Million0.34% of portfolio
-
Capital Research Global Investors Los Angeles, CA1.68MShares$90.5 Million0.02% of portfolio
-
Bank Of America Corp Charlotte, NC1.51MShares$81.5 Million0.01% of portfolio
-
State Street Corp Boston, MA1.29MShares$69.8 Million0.0% of portfolio
-
Westwood Holdings Group Inc Dallas, TX1.24MShares$66.8 Million0.6% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.08MShares$58.5 Million0.01% of portfolio
-
Macquarie Group LTD Australia, C3970KShares$52.4 Million0.06% of portfolio
Latest Institutional Activity in CNMD
Top Purchases
Top Sells
About CNMD
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and PopLok Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
Insider Transactions at CNMD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 07
2025
|
Todd W Garner Executive Vice President & CFO |
SELL
Open market or private sale
|
Direct |
598
-100.0%
|
$31,096
$52.45 P/Share
|
|
Jun 03
2025
|
Brian Concannon Director |
BUY
Exercise of conversion of derivative security
|
Direct |
479
+4.52%
|
-
|
|
Jun 03
2025
|
Barbara J Schwarzentraub Director |
BUY
Exercise of conversion of derivative security
|
Direct |
479
+9.93%
|
-
|
|
Jun 03
2025
|
Charles Farkas Director |
BUY
Exercise of conversion of derivative security
|
Direct |
479
+2.76%
|
-
|
|
Jun 03
2025
|
David M Bronson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
479
+2.7%
|
-
|
|
Jun 03
2025
|
La Verne H Council Director |
BUY
Exercise of conversion of derivative security
|
Direct |
479
+10.58%
|
-
|
|
Jun 03
2025
|
Martha Goldberg Aronson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
479
+3.72%
|
-
|
|
May 29
2025
|
Charles Farkas Director |
SELL
Payment of exercise price or tax liability
|
Direct |
966
-5.57%
|
$55,062
$57.69 P/Share
|
|
May 29
2025
|
Charles Farkas Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+5.45%
|
$55,000
$55.7 P/Share
|
|
May 20
2025
|
John L Workman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
479
+2.24%
|
$28,261
$59.84 P/Share
|
|
May 05
2025
|
Charles Farkas Director |
SELL
Open market or private sale
|
Direct |
4,000
-19.66%
|
$224,000
$56.94 P/Share
|
|
Mar 31
2025
|
Todd W Garner Executive Vice President & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
371
+38.29%
|
$21,147
$57.37 P/Share
|
|
Mar 14
2025
|
Peter K Shagory EVP, STRAT & CORP DEVT |
SELL
Payment of exercise price or tax liability
|
Direct |
4,316
-52.56%
|
$250,328
$58.83 P/Share
|
|
Mar 14
2025
|
Peter K Shagory EVP, STRAT & CORP DEVT |
BUY
Exercise of conversion of derivative security
|
Direct |
4,500
+35.4%
|
$247,500
$55.42 P/Share
|
|
Mar 07
2025
|
Brent Lalomia Vice President QA and RA |
SELL
Payment of exercise price or tax liability
|
Direct |
26
-2.52%
|
$1,612
$62.74 P/Share
|
|
Mar 07
2025
|
Brent Lalomia Vice President QA and RA |
BUY
Exercise of conversion of derivative security
|
Direct |
75
+6.78%
|
-
|
|
Feb 11
2025
|
Richard Glaze Chief Information Officer |
SELL
Open market or private sale
|
Direct |
257
-100.0%
|
$16,705
$65.35 P/Share
|
|
Nov 20
2024
|
Richard Glaze Chief Information Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
118
-31.47%
|
$8,260
$70.69 P/Share
|
|
Nov 20
2024
|
Richard Glaze Chief Information Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
375
+50.0%
|
-
|
|
Nov 07
2024
|
Curt R Hartman President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
24,303
-70.86%
|
$1,798,422
$74.76 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 40.3K shares |
|---|---|
| Grant, award, or other acquisition | 371 shares |
| Payment of exercise price or tax liability | 30.3K shares |
|---|---|
| Open market or private sale | 4.86K shares |